10x (TXG) - Full Takeover Company Value

Brandmark of 10x (TXG)

This daily price chart for 10x Genomics, Inc. (TXG) on the GURU.Markets platform reflects a company valuation of 9692.08. The modernization of automated workshops eliminates the risk of production halts for reagents. Stable supplies and the presence of manufacturing plants in Singapore and the US support the assembly of precision instruments. A leading position in spatial biology makes 10x Genomics, Inc. (TXG) tools the gold standard for genetics and oncology research.

TXG (10x) Total Company Value history from 11/23/2025 to 10/28/2026
Original product of 10x

For 10x Genomics, Inc. (TXG), enterprise value reflects the actual costs of business acquisition amid the expansion of biopharmaceutical clients. This metric aggregates market capitalization and liabilities, minus liquid assets. By analyzing the total market value assessment on GURU.Markets, an investor sees the net buyout price regardless of temporary price fluctuations. The trend of this indicator signals the extent of the premium paid for technological leadership in spatial biology. A rising trend coupled with stable demand confirms a fundamental revaluation of the company's potential.

Analysis of competing companies

Business Value Tempus AI TEM|Enterprise Value QGEN|IONS - Full Takeover Company Value|Enterprise Value Repligen Corporation|RNA (aviditybiosciences.com) - Business Value|Total Company Value CRISPR Therapeutics (CRSP)|Business Value GeneDx Holdings|Enterprise Value RARE|Enterprise Value Beam Tx (BEAM)|Enterprise Value Sarepta Therapeutics, Inc. (SRPT)|TWST - Aggregate Business Value|Intellia Therapeutics, Inc. (NTLA) - Real Price to Acquire Entire Company|Stoke Therapeutics Inc (STOK) - Business Value|Real Price to Acquire Entire Company BioLife Corp BLFS|Wave Pharma (WVE) - Value Adjusted for Debt and Cash|Maze Therapeutics Inc - Enterprise Value|Full Takeover Company Value sionnatx.com|Prime Medicine - Enterprise Value|Total Enterprise Value TSHA (Taysha Gene Therapies Inc)|QURE - Total Company Value|MeiraGTx Corp - Business Value|RGNX (REGENXBIO Inc.) - Total Company Value|SLDB: Total Enterprise Value|OCGN (Ocugen) - Total Company Value|Pacific Biosciences of California, Inc. (PACB) - Real Price to Acquire Entire Company|BNTC: Enterprise Value|Company Buyout Price Design Corp|Enterprise Value RCKT (Rocket Pharmaceuticals)|Real Price to Acquire Entire Company FDMT (4dmoleculartherapeutics.com)|Total Company Value LXEO|KRRO - Company Buyout Price|Real Price to Acquire Entire Company Editas (EDIT)|SLN - Value Adjusted for Debt and Cash|proqr.com - Enterprise Value|CDXS (Codexis) - Company Buyout Price|Total Company Value Sangamo Therapeutics, Inc. (SGMO)|Business Value Nautilus Biotechnology Inc|Enterprise Value MGX (Metagenomi, Inc)|Real Price to Acquire Entire Company precisionbiosciences.com DTIL|Real Price to Acquire Entire Company GBIO|BOLD - Company Buyout Price|Real Price to Acquire Entire Company Exicure Corp XCUR|Imunon, Inc. (IMNN) - Aggregate Business Value|Real Price to Acquire Entire Company phiopharma.com|Mustang Bio (MBIO) - Business Value|TransCode Therapeutics Inc. - Enterprise Value|Full Takeover Company Value Bionano|Enterprise Value Applied DNA Sciences, Inc. APDN|Business Value BLUE (bluebird bio Inc.)|IPA - Total Company Value|Business Value Omega Therapeutics Corp OMGA|Singular Genomics Systems - Enterprise Value|RGLS - Enterprise Value|SYRS - Enterprise Value|Aggregate Business Value Telesis Bio Inc.|Real Price to Acquire Entire Company TRACON (TCON)|Business Value Unity Biotechnology, Inc (UBX)